MDL | - |
---|---|
Molecular Weight | 584.83 |
Molecular Formula | C36H56O6 |
SMILES | OC([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@](CC[C@@]3([H])[C@]4(CC[C@]5([H])[C@@]3(CC[C@H](OC(CC(C)(C)C(O)=O)=O)C5(C)C)C)C)([H])[C@@]4(C)CC1)=O |
Bevirimat (PA-457; MPC-4326; YK FH312) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01026727 | Myrexis Inc. |
HIV Infections
|
November 2009 | Phase 2 |
NCT00967187 | Myrexis Inc. |
HIV Infections
|
May 2008 | Phase 2 |
NCT01097070 | Myrexis Inc. |
HIV-1 Infection
|
November 2008 | Phase 2 |
NCT00511368 | Myrexis Inc. |
HIV Infections
|
April 2006 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 50 mg/mL ( 85.49 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 1.7099 mL | 8.5495 mL | 17.0990 mL |
5 mM | 0.3420 mL | 1.7099 mL | 3.4198 mL |
10 mM | 0.1710 mL | 0.8549 mL | 1.7099 mL |